La Jolla Pharmaceutical won FDA approval Thursday for Giapreza, a drug that treats dangerously low blood pressure in adults with septic or other distributive shock. Here are three things to know. 1.
One in eight patients hospitalized with COVID-19 develop some form of shock, according to the American Heart Association’s COVID-19 Cardiovascular Disease Registry. And regardless of whether the shock ...
The U.S. Food and Drug Administration today approved Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure in adults with septic or other distributive shock. "Shock, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results